Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.elsevier.nl/gej-ng/10/42/35/80/48/60/abstract.html

Please note! As of 2002 online access to full-text articles is available to all readers whose library
  1. subscribes to Vaccine via ScienceDirect or
  2. has a print subscription to Vaccine and has registered for the corresponding ScienceDirect Web Editions.


Vaccine, Vol. 21 (7-8) (2003) pp. 742-745
© 2002 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(02)00593-5
 

Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN "NEW" in children: results of post-marketing surveillance

Borislava G. Pavlova * borislava_pavlova@baxter.com , Alexandra Loew-Baselli 1 , Sandor Fritsch 1, Eva-Maria Poellabauer 1, Nina Vartian 1, Ingeborg Rinke 1 and Hartmut J. Ehrlich 2 hartmut_ehrlich@baxter.com

Baxter BioScience Vaccines, Clinical Development and Medical Affairs, Industriestr. 67, A-1221 Vienna, Austria

Abstract

A new, highly purified, inactivated tick-borne encephalitis (TBE) vaccine FSME-IMMUN "NEW" has been developed by Baxter using a production virus seed derived from chick embryo cells instead of mouse brain. In clinical trials, the vaccine was shown to be highly immunogenic and well tolerated in adults and children. Following licensure in 2001, the tolerability of half the adult dose of FSME-IMMUN "NEW" (1.2µg antigen/0.25ml) was investigated in a post-marketing surveillance in 1899 children aged 6 months to 12 years. Rectal body temperature was measured daily for 3 days after the first vaccination. An overall fever rate of 20.3% (95% CI=18.5; 22%) was observed, which was mostly mild in nature (>38.0 to <=39.0°C) with only 0.3% (95% CI=0.1; 0.6%) severe cases reported. The highest fever rates were reported in February and March (when febrile illnesses are common) and in the 1-3 years age group (63% of the total surveillance population). These results demonstrated that, in routine medical practice, FSME-IMMUN "NEW" vaccine at a dose of 1.2µg antigen/0.25ml is safe for the first vaccination in children.

Keywords: Tick-borne encephalitis (TBE); FSME-IMMUN "NEW"; Post-marketing surveillance; Fever rate

*Corresponding author. Tel.: +43-1-20-100-3298; fax: +43-1-20-100-534.

1Tel.: +43-1-20-100; fax: +43-1-20-100-534.

2Tel.: +43-1-20-100-2420; fax: +43-1-20-100-534.

Full text supplied by [ScienceDirect]

© Copyright 2003, Elsevier Science, All rights reserved.

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.